Advertisement

Haemonetics (NYSE: HAE), a blood management company, must delay the closing of its acquisition of Hemerus Medical, after the U.S. Food and Drug Administration delayed approval of a Hemerus product. The acquisition is contingent on the FDA approval.

Advertisement
Advertisement